155 related articles for article (PubMed ID: 29767862)
1. Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.
Niu J; Kundranda MN; Markman M; Farley J
Eur J Gynaecol Oncol; 2017; 38(1):40-44. PubMed ID: 29767862
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.
Lund B; Hansen OP; Neijt JP; Theilade K; Hansen M
Anticancer Drugs; 1995 Dec; 6 Suppl 6():61-2. PubMed ID: 8718427
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Nagao S; Kogiku A; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
J Ovarian Res; 2020 Feb; 13(1):14. PubMed ID: 32028974
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Wright JD; Hagemann A; Rader JS; Viviano D; Gibb RK; Norris L; Mutch DG; Powell MA
Cancer; 2006 Jul; 107(1):83-9. PubMed ID: 16736514
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Li Y; Yang Y; Shang YM; Zheng H
Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
[TBL] [Abstract][Full Text] [Related]
7. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
Simpkins F; Belinson JL; Rose PG
Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
[TBL] [Abstract][Full Text] [Related]
8. Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Takasaki K; Miyamoto M; Takano M; Soyama H; Aoyama T; Matsuura H; Kato K; Sakamoto T; Kuwahara M; Iwahashi H; Ishibashi H; Yoshikawa T; Furuya K
Cancer Chemother Pharmacol; 2018 May; 81(5):809-814. PubMed ID: 29500481
[TBL] [Abstract][Full Text] [Related]
9. A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W
J Obstet Gynaecol Res; 2003 Jun; 29(3):123-31. PubMed ID: 12841693
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
Eisenhauer EL; Zanagnolo V; Cohn DE; Salani R; O'Malley DM; Sutton G; Callahan MJ; Cobb B; Fowler JM; Copeland LJ
Gynecol Oncol; 2014 Aug; 134(2):262-6. PubMed ID: 24910452
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.
Yoshino K; Hiramatsu K; Enomoto T; Fujita M; Ueda Y; Kimura T; Kobayashi E; Kiyohara Y; Tsutsui T; Kimura T
Anticancer Res; 2012 Sep; 32(9):4029-33. PubMed ID: 22993355
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.
Ferrero A; Logrippo V; Spanu PG; Fuso L; Perotto S; Daniele A; Zola P
Int J Gynecol Cancer; 2009 Dec; 19(9):1529-34. PubMed ID: 19955931
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Raspagliesi F; Zanaboni F; Vecchione F; Hanozet F; Scollo P; Ditto A; Grijuela B; Fontanelli R; Solima E; Spatti G; Scibilia G; Kusamura S
Oncology; 2004; 67(5-6):376-81. PubMed ID: 15713993
[TBL] [Abstract][Full Text] [Related]
14. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH
Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of gemcitabine combined with platinum chemotherapy for recurrent epithelial ovarian cancer.
Peng P; Shen K; Yang JX; Wu M; Huang HF; Pan LY; Lang JH
Chin Med Sci J; 2007 Sep; 22(3):177-82. PubMed ID: 17966166
[TBL] [Abstract][Full Text] [Related]
17. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.
Kodaz H; Hacibekiroglu I; Turkmen E; Erdogan B; Elpen C; Uzunoglu S; Cicin I
Tumori; 2015; 101(1):36-40. PubMed ID: 25702671
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2003 Sep; 90(3):593-6. PubMed ID: 13678730
[TBL] [Abstract][Full Text] [Related]
20. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
Villella J; Marchetti D; Odunsi K; Rodabaugh K; Driscoll DL; Lele S
Gynecol Oncol; 2004 Dec; 95(3):539-45. PubMed ID: 15581960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]